CORDIS
EU research results

CORDIS

English EN

Genes And Proteins for AutoImmunity Diagnostics

Objective

"Rheumatoid arthritis (RA) and sistemic lupus erythematosus (SLE) are two autoimmune diseases that respectively affect an estimated population of 1.537.000 and 1.272.000 of patients in Europe. Such diseases show a long prodrome during which there are no clinical symptoms. In some cases, therapeutic treatments have been developed to improve patients quality of life. Therefore, reliable diagnostic/prognostic tools are necessary not only for an early diagnosis and for monitoring disease activity, but also for setting up personalized therapeutic treatments.
The clinical diagnosis of RA and SLE is assisted by the use of in vitro diagnostic tests aimed at the evaluation of the presence/level of few autoantibodies circulating in serum. Yet, this diagnostic approach is unsatisfactory because it can assist the diagnosis only after the first disease onset, it is not useful to evaluate the disease susceptibility for an early prevention, and it does not provide information to follow the disease progression for the set up of personalized therapeutic treatments.
To solve these drawbacks, the GAPAID project is aimed at supplying the SME participants of the scientific and technological activities necessary to develop a novel diagnostic / prognostic platform for patients affected by RA and SLE. To this aim the scientific activities will be focused on the discovery of the diagnostic and prognostic value of the genetic and serological profiles associated to RA and SLE. The technological activities will contribute to develop multiplex arrays for the contemporary detection of more analytes and to set up a software for the RA and SLE diagnosis / prognosis by matching the clinical, genetic, and serological data. The exploitation of the scientific and technological results will allow the SME participants to the GAPAID proposal to develop and to further commercialize both for RA and SLE an in vitro diagnostic product composed by a genetic array, a serological array, and a software."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

TOSCANA BIOMARKERS S.R.L

Address

Via Fiorentina 1
53100 Siena

Italy

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 181 015,82

Administrative Contact

Maria Claudia Alcaro (Dr.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

PROGENIKA BIOPHARMA SA

Spain

EU Contribution

€ 581 507,61

DIAGNOSTICUM GYARTO ES FORGALMAZO ZARTKORUEN MUKODO RESZVENYTARSASAG

Hungary

EU Contribution

€ 194 371,32

UNIVERSITA DI PISA

Italy

EU Contribution

€ 13 472

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA

Spain

OMNILAB IBERIA SL

Spain

EU Contribution

€ 30 586

EOTVOS LORAND TUDOMANYEGYETEM

Hungary

PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS

Hungary

Pharma Quality Europe S.R.L.

Italy

EU Contribution

€ 209 047,25

Project information

Grant agreement ID: 314971

Status

Closed project

  • Start date

    1 September 2012

  • End date

    31 August 2014

Funded under:

FP7-SME

  • Overall budget:

    € 1 715 535,96

  • EU contribution

    € 1 210 000

Coordinated by:

TOSCANA BIOMARKERS S.R.L

Italy